IMO. DYOR.
I think a key to closing some of this share price gap will likely be a partnership with an upfront cash payment plus various clinical development and commercial milestones.
Partnerships can come with US $50M plus upfront cash payments. An upfront + milestones partnership would fund pivotal trials and potentially be a stepping stone to a buyout transaction.
RACE shared the following deal examples in 2021 ( and these were preclinical stage ) - these also in the emerging RNA regulation space RACE is partly focused on.
Zantrene is also not a “me too” drug. RACE with FTO and cardioprotection ( with improved cancer killing ) seems to be firmly establishing a lead position in key Oncology Real Estate … targeting FTO for a large number of cancers and a better ( and importantly safer ) chemo regimen to replace the mainstream AC regimen. RACE have been undertaking their own preclinical programs to show improved efficacy / safety and have various programs to validate this through proof of concept clinical trials.
Note - above slide is from a July 2022 Torreya presentation available here:
https://torreya.com/publications/Torreya-Oncology-Marketplace-Update-July_19_2022.pdf
IMO. DYOR. I think a key to closing some of this share price gap...
-
- There are more pages in this discussion • 134 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.44 |
Change
0.040(2.86%) |
Mkt cap ! $245.3M | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.49 | $1.41 | $101.7K | 69.88K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9216 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.47 | 7767 | 2 |
View Market Depth
| Last trade - 16.10pm 09/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |